{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:26:32Z","timestamp":1793942792458,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"crossref","award":["HL159156"],"award-info":[{"award-number":["HL159156"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Keloid formation following trauma or surgery is common among darkly pigmented individuals. Since lipoprotein(a) [Lp(a)] has been postulated to have a putative role in wound healing, and also mediates atherosclerotic cardiovascular disease, it was assessed whether Lp(a), its associated oxidized phospholipids and other oxidation-specific biomarkers were associated with keloid formation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This case-control study included darkly pigmented individuals of African ancestry, 100 with keloid scarring and 100 non-keloid controls. The lipid panel, hsCRP, Lp(a), oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB), IgG and IgM apoB-immune complexes and IgG and IgM autoantibodies to a malondialdehyde mimotope (MDA-mimotope) were measured. Immunohistochemistry of keloid specimens was performed for both Lp(a) and OxPL staining.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cases and controls were well matched for age, sex and lipid profile. Mean Lp(a) (57.8 vs. 44.2\u00a0mg\/dL; <jats:italic>P<\/jats:italic>\u2009=\u20090.01, OxPL-apoB 17.4 vs. 15.7 nmol\/L; <jats:italic>P<\/jats:italic>\u2009=\u20090.009) and IgG and IgM apoB-immune complexes and IgG and IgM MDA-mimotope levels were significantly higher in keloid cases. Keloid tissue stained strongly for OxPL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Darkly pigmented individuals of African ancestry with keloids have higher plasma levels of Lp(a), OxPL-apoB and oxidation-specific epitopes. The commonality of excessive wound healing in keloids and chronic complications from coronary revascularization suggests avenues of investigation to define a common mechanism driven by Lp(a) and the innate response to oxidized lipids.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-022-01720-z","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T06:02:38Z","timestamp":1667282558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation"],"prefix":"10.1186","volume":"21","author":[{"given":"Sundeep","family":"Ruder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Ronald","family":"Immelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissi","family":"Varki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Miu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"issue":"8","key":"1720_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). J Lipid Res. 2016;57(8):1339\u201359.","journal-title":"J Lipid Res"},{"issue":"4","key":"1720_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u201323.","journal-title":"JAMA"},{"issue":"26","key":"1720_CR3","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"22","key":"1720_CR4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20139.","journal-title":"JAMA"},{"issue":"6","key":"1720_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","volume":"368","author":"G Thanassoulis","year":"2013","unstructured":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503\u201312.","journal-title":"N Engl J Med"},{"issue":"11","key":"1720_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","volume":"66","author":"R Capoulade","year":"2015","unstructured":"Capoulade R, Chan KL, Yeang C, Mathieu P, Bosse Y, Dumesnil JG, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66(11):1236\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1720_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1720_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.R060582","volume":"57","author":"MB Boffa","year":"2016","unstructured":"Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57(5):745\u201357.","journal-title":"J Lipid Res"},{"issue":"7","key":"1720_CR9","doi-asserted-by":"publisher","first-page":"e1004494","DOI":"10.1371\/journal.pgen.1004494","volume":"10","author":"ET Lim","year":"2014","unstructured":"Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 2014;10(7):e1004494.","journal-title":"PLoS Genet"},{"issue":"25","key":"1720_CR10","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","volume":"68","author":"CA Emdin","year":"2016","unstructured":"Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol. 2016;68(25):2761\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1720_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","volume":"56","author":"S Mora","year":"2010","unstructured":"Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56(8):1252\u201360.","journal-title":"Clin Chem"},{"issue":"3","key":"1720_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","volume":"1","author":"PR Kamstrup","year":"2013","unstructured":"Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1(3):220\u20137.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1720_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2337\/db13-1144","volume":"63","author":"Z Ye","year":"2014","unstructured":"Ye Z, Haycock PC, Gurdasani D, Pomilla C, Boekholdt SM, Tsimikas S, et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes. 2014;63(1):332\u201342.","journal-title":"Diabetes"},{"issue":"11","key":"1720_CR14","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","volume":"36","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 Patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6144","key":"1720_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/330113a0","volume":"330","author":"MS Brown","year":"1987","unstructured":"Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987;330(6144):113\u20134.","journal-title":"Nature"},{"issue":"6144","key":"1720_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","volume":"330","author":"JW McLean","year":"1987","unstructured":"McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132\u20137.","journal-title":"Nature"},{"issue":"49","key":"1720_CR17","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1021\/bi00212a037","volume":"32","author":"JL Hoover-Plow","year":"1993","unstructured":"Hoover-Plow JL, Miles LA, Fless GM, Scanu AM, Plow EF. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry. 1993;32(49):13681\u20137.","journal-title":"Biochemistry"},{"issue":"2","key":"1720_CR18","doi-asserted-by":"publisher","first-page":"E95","DOI":"10.25011\/cim.v32i2.6026","volume":"32","author":"S Bhavsar","year":"2009","unstructured":"Bhavsar S, Nimigan A, Hackam DG, O\u2019Gorman DB, Gan BS, Spence JD. Keloid scarring, but not Dupuytren\u2019s contracture, is associated with unexplained carotid atherosclerosis. Clin Invest Med Med clinique et experimentale. 2009;32(2):E95\u2013102.","journal-title":"Clin Invest Med Med clinique et experimentale"},{"issue":"5","key":"1720_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/01.ATV.9.5.579","volume":"9","author":"M Rath","year":"1989","unstructured":"Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9(5):579\u201392.","journal-title":"Arteriosclerosis"},{"issue":"12","key":"1720_CR20","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1194\/jlr.P030890","volume":"53","author":"RA van Dijk","year":"2012","unstructured":"van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012;53(12):2773\u201390.","journal-title":"J Lipid Res"},{"issue":"2","key":"1720_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/hrt.78.2.131","volume":"78","author":"JS Skinner","year":"1997","unstructured":"Skinner JS, Farrer M, Albers CJ, Piper K, Neil HA, Adams PC. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart. 1997;78(2):131\u20135.","journal-title":"Heart"},{"issue":"5","key":"1720_CR22","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.ijcard.2012.05.007","volume":"167","author":"SW Kwon","year":"2013","unstructured":"Kwon SW, Lee BK, Hong BK, Kim JY, Choi EY, Sung JM, et al. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. Int J Cardiol. 2013;167(5):1990\u20134.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1720_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2014.05.944","volume":"235","author":"MV Ezhov","year":"2014","unstructured":"Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235(2):477\u201382.","journal-title":"Atherosclerosis"},{"issue":"18","key":"1720_CR24","first-page":"2059","volume":"14","author":"Y-H Yoon","year":"2021","unstructured":"Yoon Y-H, Ahn J-M, Kang D-Y, Lee PH, Kang S-J, Park D-W, et al. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention. JACC: Cardiovasc Interv. 2021;14(18):2059\u201368.","journal-title":"JACC: Cardiovasc Interv"},{"issue":"6","key":"1720_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1440-1681.12396","volume":"42","author":"SH Park","year":"2015","unstructured":"Park SH, Rha SW, Choi BG, Park JY, Jeon U, Seo HS, et al. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clin Exp Pharmacol Physiol. 2015;42(6):588\u201395.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"8","key":"1720_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/clc.21988","volume":"35","author":"I Kardys","year":"2012","unstructured":"Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, et al. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol. 2012;35(8):482\u20139.","journal-title":"Clin Cardiol"},{"issue":"25","key":"1720_CR27","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","volume":"109","author":"S Tsimikas","year":"2004","unstructured":"Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109(25):3164\u201370.","journal-title":"Circulation"},{"issue":"21","key":"1720_CR28","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.jacc.2013.02.047","volume":"61","author":"ML Bertoia","year":"2013","unstructured":"Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013;61(21):2169\u201379.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1720_CR29","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1194\/jlr.M015776","volume":"52","author":"A Ravandi","year":"2011","unstructured":"Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011;52(10):1829\u201336.","journal-title":"J Lipid Res"},{"issue":"7","key":"1720_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1194\/jlr.M025445","volume":"53","author":"S Amir","year":"2012","unstructured":"Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E, et al. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J Lipid Res. 2012;53(7):1316\u201326.","journal-title":"J Lipid Res"},{"issue":"3","key":"1720_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jacbts.2017.02.004","volume":"2","author":"M Torzewski","year":"2017","unstructured":"Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, et al. Lipoprotein(a) associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis. JACC Basic Transl Sci. 2017;2(3):229\u201340.","journal-title":"JACC Basic Transl Sci"},{"issue":"1\u20132","key":"1720_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2119\/molmed.2009.00153","volume":"17","author":"GG Gauglitz","year":"2011","unstructured":"Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17(1\u20132):113\u201325.","journal-title":"Mol Med"},{"issue":"9","key":"1720_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","volume":"80","author":"S Tsimikas","year":"2022","unstructured":"Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80(9):934\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1720_CR34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1006\/bbrc.1993.1343","volume":"191","author":"SM Marcovina","year":"1993","unstructured":"Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191(3):1192\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"1720_CR35","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","volume":"119","author":"S Tsimikas","year":"2009","unstructured":"Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009;119(13):1711\u20139.","journal-title":"Circulation"},{"issue":"13","key":"1720_CR36","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","volume":"65","author":"YS Byun","year":"2015","unstructured":"Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015;65(13):1286\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1720_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jacc.2016.10.057","volume":"69","author":"YS Byun","year":"2017","unstructured":"Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, et al. Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack. J Am Coll Cardiol. 2017;69(2):147\u201358.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1720_CR38","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","volume":"63","author":"S Tsimikas","year":"2014","unstructured":"Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014;63(17):1724\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"10057","key":"1720_CR39","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239\u201353.","journal-title":"Lancet"},{"issue":"3","key":"1720_CR40","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"1720_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbalip.2017.01.006","volume":"1862","author":"CJ Binder","year":"2017","unstructured":"Binder CJ. Lipid modification and lipid peroxidation products in innate immunity and inflammation. Biochim Biophys Acta. 2017;1862(4):369\u201370.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1720_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","volume":"41","author":"S Tsimikas","year":"2003","unstructured":"Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1720_CR43","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/01.ATV.0000149378.98458.fe","volume":"24","author":"M Torzewski","year":"2004","unstructured":"Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol. 2004;24(12):2307\u201312.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1720_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/01.ATV.0000251501.86410.03","volume":"27","author":"S Tsimikas","year":"2007","unstructured":"Tsimikas S, Aikawa M, Miller FJ Jr, Miller ER, Torzewski M, Lentz SR, et al. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2007;27(1):175\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1720_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0002-8703(94)90522-3","volume":"127","author":"R Virmani","year":"1994","unstructured":"Virmani R, Farb A, Burke AP. Coronary angioplasty from the perspective of atherosclerotic plaque: morphologic predictors of immediate success and restenosis. Am Heart J. 1994;127(1):163\u201379.","journal-title":"Am Heart J"},{"issue":"6489","key":"1720_CR46","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/370460a0","volume":"370","author":"DJ Grainger","year":"1994","unstructured":"Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370(6489):460\u20132.","journal-title":"Nature"},{"issue":"53","key":"1720_CR47","doi-asserted-by":"publisher","first-page":"55187","DOI":"10.1074\/jbc.M409860200","volume":"279","author":"CH O\u2019Neil","year":"2004","unstructured":"O\u2019Neil CH, Boffa MB, Hancock MA, Pickering JG, Koschinsky ML. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem. 2004;279(53):55187\u201395.","journal-title":"J Biol Chem"},{"issue":"1","key":"1720_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.carrev.2011.08.001","volume":"13","author":"P Fefer","year":"2012","unstructured":"Fefer P, Tsimikas S, Segev A, Sparkes J, Otsuka F, Kolodgie F, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med. 2012;13(1):11\u20139.","journal-title":"Cardiovasc Revasc Med"},{"issue":"19","key":"1720_CR49","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","volume":"63","author":"A Ravandi","year":"2014","unstructured":"Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol. 2014;63(19):1961\u201371.","journal-title":"J Am Coll Cardiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-022-01720-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T18:04:22Z","timestamp":1667325862000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-022-01720-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1186\/s12944-022-01720-z","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was by the ethics committee of the University of the Witwatersrand.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors contributed significantly to the manuscript for intellectual content and provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ST is a co-inventor and receives royalties from patents owned by UCSD on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins, is a co-founder and has an equity interest in Oxitope, Inc and its affiliates (\u201cOxitope\u201d), Kleanthi Diagnostics, LLC (\u201cKleanthi\u201d) and Covicept Therapeutics. Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Oxitope and Kleanthi, the research findings included in this particular publication may not necessarily relate to the interests of Oxitope and Kleanthi. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The other authors have no conflicts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}